A Raleigh company that sells a blood test to measure patients' risk for heart disease is reviving plans for an initial public offering of stock.

LipoScience wants to raise $86.25 million in an IPO, the company disclosed in a Securities and Exchange Commission filing.

The company first filed IPO plans in 2002, but scrapped them after failing to attract enough interest on Wall Street. This time, LipoScience officials are hoping that having a few more years of steady revenue growth will help sell their story to investors. They're also counting on renewed interest in IPOs.

Founded in 1994 based on research at N.C. State University, LipoScience's main product is the NMR LipoProfile, a diagnostic test that checks the levels of bad cholesterol in the blood.

Following on a blog post from last week...

The Gillings School of Global Public Health at UNC-Chapel Hill will pay former Blue Cross Blue Shield North Carolina CEO Robert Greczyn up to $50,000 for his work as a visiting professor there.

Greczyn became a visiting professor Oct. 1 and will lecture on insurance, health care and health care reform and is expected to serve as a policy advisor and resource for the school and its students.

His exact pay depends on just how many classes he teaches and projects he works on, but will likely be less than $50,000 for the year, said Ramona Dubose, a spokeswoman for the school.

He's on a one-year contract renewable for a second year and will be paid from private funds, Dubose said.